Skip to main content


Fig. 4 | Health and Quality of Life Outcomes

Fig. 4

From: Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies

Fig. 4

Results of the PAM-D21-J and IDMQ-J at Week 26 in the Combination Therapy Study. (a) PAM-D21-J at week 26 (LSM scores by treatment). (b) IDMQ-J at week 26 (LSM scores by treatment). IDMQ-J Injectable Diabetes Medication Questionnaire - Japanese version; LSM, least-squares mean; PAM-D21-J Perceptions About Medications-Diabetes 21 Questionnaire - Japanese version. Dulaglutide administered once weekly; insulin glargine administered once daily. For all subscales higher scores represent a more favorable state. *p < .05 vs. insulin glargine, **p < .001 vs. insulin glargine

Back to article page